Lymphoma associated hemophagocytic syndrome: A single‑center retrospective study

Chang,Yu; Cui,Meng; Fu,Xiaorui; Han,Lijuan; Zhang,Lei; Li,Ling; Li,Xin; Sun,Zhenchang; Wu,Jingjing; Zhang,Xudong; Li,Zhaoming; Nan,Feifei; Yan,Jiaqin; Sheng,Guangyao; Zhang,Mingzhi

doi:10.3892/ol.2018.8783

Lymphoma associated hemophagocytic syndrome: A single‑center retrospective study

Authors:
- Yu Chang
- Meng Cui
- Xiaorui Fu
- Lijuan Han
- Lei Zhang
- Ling Li
- Xin Li
- Zhenchang Sun
- Jingjing Wu
- Xudong Zhang
- Zhaoming Li
- Feifei Nan
- Jiaqin Yan
- Guangyao Sheng
- Mingzhi Zhang
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Department of Head and Neck and Thyroid, Henan Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: May 22, 2018 https://doi.org/10.3892/ol.2018.8783
Pages: 1275-1284

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To improve the understanding of lymphoma associated hemophagocytic syndrome (LAHS) and find an effective treatment for this fatal disease, 57 patients with LAHS were retrospectively reviewed. The most common histopathological type was extranodal natural killer (NK)/T‑cell lymphoma, nasal type (ENKL) (45.61%). Patients with B‑cell LAHS were significantly older (P<0.001), and exhibited a higher triglyceride level (P=0.012), lower serum ferritin level (P=0.014) and lower plasma Epstein‑Barr virus DNA (P<0.001) compared with patients with T/NK‑cell LAHS. The median survival time of all patients was 43 days, and patients with B‑cell (n=14) and T/NK‑cell (n=43) LAHS had a median survival time of 55 and 40 days, respectively (P=0.797). Compared with patients who were treated based on HLH‑2004 protocols combined with multidrug chemotherapy, those without chemotherapy had a reduced prognosis (P=0.002). The patients that underwent hematopoietic stem cell transplantation (HSCT) following chemotherapy had a significantly improved overall survival (OS) compared with patients that did not undergo HSCT (P=0.001). Patients with B‑cell LAHS treated with rituximab (P=0.015) and patients with ENKL treated with L‑asparaginase/pegaspargase (L‑asp/peg) (P=0.009) had an improved prognosis compared with patients not treated with these drugs. In the T/NK‑cell LAHS group, patients treated with chemotherapy containing gemcitabine did not exhibit an improved OS compared with those not treated with gemcitabine (P=0.326). Furthermore, multivariate analysis demonstrated that long diagnosis time and poor performance status were independent prognosis factors for all patients with LAHS. The present study indicated that survival time does not differ between patients with B‑cell LAHS and patients with T/NK‑cell LAHS. Early diagnosis and appropriate immunochemotherapy plus HSCT are essential to achieve improved outcomes. The outcome of patients with B‑cell LAHS may be significantly improved following treatment with rituximab. L‑asp/peg‑containing regimens are promising treatments for patients with NK/T‑cell LAHS.

View Figures

View References

1	Risdall RJ, McKenna RW, Nesbit ME, Krivit W, Balfour HJ, Simmons RL and Brunning RD: Virus-associated hemophagocytic syndrome: A benign histiocytic proliferation distinct from malignant histiocytosis. Cancer. 3:993–1002. 1979. View Article : Google Scholar
2	Szyper-Kravitz M: The hemophagocytic syndrome/macrophage activation syndrome: A final common pathway of a cytokine storm. Isr Med Assoc J. 10:633–634. 2009.
3	Janka GE and Lehmberg K: Hemophagocytic lymphohistiocytosis: Pathogenesis and treatment. Hematology Am Soc Hematol Educ Program. 2013:605–611. 2013.PubMed/NCBI
4	Rouphael NG, Talati NJ, Vaughan C, Cunningham K, Moreira R and Gould C: Infections associated with haemophagocytic syndrome. Lancet Infect Dis. 12:814–822. 2007. View Article : Google Scholar
5	Janka GE and Lehmberg K: Hemophagocytic syndromes-an update. Blood Rev. 4:135–142. 2014. View Article : Google Scholar
6	Han L, Li L, Wu J, Li X, Zhang L, Wang X, Fu X, Ma W, Sun Z, Zhang X, et al: Clinical features and treatment of natural killer/T cell lymphoma associated with hemophagocytic syndrome: Comparison with other T cell lymphoma associated with hemophagocytic syndrome. Leuk Lymphoma. 9:2048–2055. 2014. View Article : Google Scholar
7	Parikh SA, Kapoor P, Letendre L, Kumar S and Wolanskyj AP: Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc. 89:484–492. 2014. View Article : Google Scholar : PubMed/NCBI
8	Han AR, Lee HR, Park BB, Hwang IG, Park S, Lee SC, Kim K, Lim HY, Ko YH, Kim SH and Kim WS: Lymphoma-associated hemophagocytic syndrome: Clinical features and treatment outcome. Ann Hematol. 86:493–498. 2007. View Article : Google Scholar : PubMed/NCBI
9	Sano H, Kobayashi R, Tanaka J, Hashino S, Ota S, Torimoto Y, Kakinoki Y, Yamamoto S, Kurosawa M, Hatakeyama N, et al: Risk factor analysis of non-Hodgkin lymphoma-associated haemophagocytic syndromes: A multicentre study. Br J Haematol. 165:786–792. 2014. View Article : Google Scholar : PubMed/NCBI
10	Tabata C and Tabata R: Possible prediction of underlying lymphoma by high sIL-2R/ferritin ratio in hemophagocytic syndrome. Ann Hematol. 91:63–71. 2012. View Article : Google Scholar : PubMed/NCBI
11	Seo JJ: Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: Recent advances and controversies. Blood Res. 50:131–139. 2015. View Article : Google Scholar : PubMed/NCBI
12	Sabattini E, Bacci F, Sagramoso C and Pileri SA: WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: An overview. Pathologica. 102:83–87. 2010.PubMed/NCBI
13	Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J and Janka G: HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 48:124–131. 2007. View Article : Google Scholar : PubMed/NCBI
14	Olweny CL: Cotswolds modification of the Ann Arbor staging system for Hodgkin's disease. J Clin Oncol. 9:15981990.
15	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
16	Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, et al: Revised response criteria for malignant lymphoma. J Clin Oncol. 25:579–586. 2007. View Article : Google Scholar : PubMed/NCBI
17	Takahashi N, Chubachi A, Miura I, Nakamura S and Miura AB: Lymphoma-associated hemophagocytic syndrome in Japan. Rinsho Ketsueki. 40:542–549. 1999.(In Japanese). PubMed/NCBI
18	Yu JT, Wang CY, Yang Y, Wang RC, Chang KH, Hwang WL and Teng CL: Lymphoma-associated hemophagocytic lymphohistiocytosis: Experience in adults from a single institution. Ann Hematol. 11:1529–1536. 2013. View Article : Google Scholar
19	Tong H, Ren Y, Liu H, Xiao F, Mai W, Meng H, Qian W, Huang J, Mao L, Tong Y, et al: Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: Comparison of T-cell lymphoma with and without hemophagocytic syndrome. Leuk Lymphoma. 49:81–87. 2008. View Article : Google Scholar : PubMed/NCBI
20	Allen CE, Yu X, Kozinetz CA and McClain KL: Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 50:1227–1235. 2008. View Article : Google Scholar : PubMed/NCBI
21	Chen YP, Jones D, Chen TY and Chang KC: Epstein-Barr virus present in T cells or B cells shows differential effects on hemophagocytic symptoms associated with outcome in T-cell lymphomas. Leuk Lymphoma. 55:2038–2047. 2014. View Article : Google Scholar : PubMed/NCBI
22	Kwong YL, Pang AW, Leung AY, Chim CS and Tse E: Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: Diagnostic and prognostic significance. Leukemia. 28:865–870. 2014. View Article : Google Scholar : PubMed/NCBI
23	Suzuki R, Yamaguchi M, Izutsu K, Yamamoto G, Takada K, Harabuchi Y, Isobe Y, Gomyo H, Koike T, Okamoto M, et al: Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood. 118:6018–6022. 2011. View Article : Google Scholar : PubMed/NCBI
24	Ohno T, Ueda Y, Nagai K, Takahashi T, Konaka Y, Takamatsu T, Suzuki T, Sasada M and Uchiyama T; Kyoto University Hematology/Oncology Study Group: The serum cytokine profiles of lymphoma-associated hemophagocytic syndrome: A comparative analysis of B-cell and T-cell/natural killer cell lymphomas. Int J Hematol. 77:286–294. 2003. View Article : Google Scholar : PubMed/NCBI
25	Chuang HC, Lay JD, Hsieh WC and Su IJ: Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein-Barr virus-associated T-cell lymphoma: Nuclear factor-kappa B pathway as a potential therapeutic target. Cancer Sci. 98:1281–1287. 2007. View Article : Google Scholar : PubMed/NCBI
26	Barba T, Maucort-Boulch D, Iwaz J, Bohé J, Ninet J, Hot A, Lega JC, Guérin C, Argaud L, Broussolle C, et al: Hemophagocytic Lymphohistiocytosis in intensive care unit: A 71-case strobe-compliant retrospective study. Medicine (Baltimore). 94:e23182015. View Article : Google Scholar : PubMed/NCBI
27	Cattaneo C, Oberti M, Skert C, Passi A, Farina M, Re A, Tozzi P, Borlenghi E and Rossi G: Adult onset hemophagocytic lymphohistiocytosis prognosis is affected by underlying disease and coexisting viral infection: Analysis of a single institution series of 35 patients. Hematol Oncol. 35:828–834. 2017. View Article : Google Scholar : PubMed/NCBI
28	Yiu CR, Kao YH, Phipps C and Tan D: Positron emission tomography findings in patients with lymphoma-associated haemophagocytic syndrome. Singapore Med J. 7:e156–e159. 2011.
29	Zhang LJ, Xu J, Liu P, Ding CY, Li JY, Qiu HX and Zhang SJ: The significance of 18F-FDG PET/CT in secondary hemophagocytic lymphohistiocytosis. J Hematol Oncol. 5:402012. View Article : Google Scholar : PubMed/NCBI
30	Yang YQ, Ding CY, Xu J, Fan L, Wang L, Tian T, Li TN, Li JY and Xu W: Exploring the role of bone marrow increased FDG uptake on PET/CT in patients with lymphoma-associated hemophagocytic lymphohistiocytosis: A reflection of bone marrow involvement or cytokine storm? Leuk Lymphoma: Jun 19, 1–8, 2015 (Epub ahead of print).
31	Maruoka H, Inoue D, Takiuchi Y, Nagano S, Arima H, Tabata S, Matsushita A, Ishikawa T, Oita T and Takahashi T: IP-10/CXCL10 and MIG/CXCL9 as novel markers for the diagnosis of lymphoma-associated hemophagocytic syndrome. Ann Hematol. 3:393–401. 2014. View Article : Google Scholar
32	Henter JI, Arico M, Egeler RM, Elinder G, Favara BE, Filipovich AH, Gadner H, Imashuku S, Janka-Schaub G, Komp D, et al: HLH-94: A treatment protocol for hemophagocytic lymphohistiocytosis. HLH study group of the histiocyte society. Med Pediatr Oncol. 28:342–347. 1997. View Article : Google Scholar
33	Park BB, Kim WS, Suh C, Shin DY, Kim JA, Kim HG and Lee WS: Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: A consortium for improving survival of lymphoma (CISL) trial. Ann Hematol. 94:1845–1851. 2015. View Article : Google Scholar : PubMed/NCBI
34	Pellegrini C, Dodero A, Chiappella A, Monaco F, Degl'Innocenti D, Salvi F, Vitolo U, Argnani L, Corradini P and Zinzani PL; Italian Lymphoma Foundation (Fondazione Italiana Linfomi Onlus, FIL): A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. J Hematol Oncol. 9:382016. View Article : Google Scholar : PubMed/NCBI
35	Li X, Cui Y, Sun Z, Zhang L, Li L, Wang X, Wu J, Fu X, Ma W, Zhang X, et al: DDGP versus SMILE in newly diagnosed advanced natural Killer/T cell lymphoma: A randomized controlled, multicenter, Open-label study in China. Clin Cancer Res. 22:5223–5228. 2016. View Article : Google Scholar : PubMed/NCBI
36	Li L, Zhang C, Zhang L, Li X, Wu JJ, Sun ZC, Fu XR, Wang XH, Chang Y, Wang R, et al: Efficacy of a pegaspargase-based regimen in the treatment of newly-diagnosed extranodal natural killer/T-cell lymphoma. Neoplasma. 61:225–232. 2014. View Article : Google Scholar : PubMed/NCBI
37	Zhou Z, Li X, Chen C, Li X, Zhang L, Li L, Wang X, Ma W, Fu X, Wu J, et al: Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: A retrospective study of 17 patients. Ann Hematol. 93:1889–1894. 2014. View Article : Google Scholar : PubMed/NCBI
38	Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, Leung AY and Chim CS: SMILE for natural killer/T-cell lymphoma: Analysis of safety and efficacy from the Asia lymphoma study group. Blood. 120:2973–2980. 2012. View Article : Google Scholar : PubMed/NCBI
39	Trottestam H, Horne A, Arico M, Egeler RM, Filipovich AH, Gadner H, Imashuku S, Ladisch S, Webb D, Janka G, et al: Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: Long-term results of the HLH-94 treatment protocol. Blood. 118:4577–4584. 2011. View Article : Google Scholar : PubMed/NCBI
40	Marsh RA, Vaughn G, Kim MO, Li D, Jodele S, Joshi S, Mehta PA, Davies SM, Jordan MB, Bleesing JJ and Filipovich AH: Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 116:5824–5831. 2010. View Article : Google Scholar : PubMed/NCBI
41	Machaczka M, Nahi H, Karbach H, Klimkowska M and Hagglund H: Successful treatment of recurrent malignancy-associated hemophagocytic lymphohistiocytosis with a modified HLH-94 immunochemotherapy and allogeneic stem cell transplantation. Med Oncol. 29:1231–1236. 2012. View Article : Google Scholar : PubMed/NCBI
42	Inoue D, Nagai Y, Takiuchi Y, Nagano S, Arima H, Kimura T, Shimoji S, Mori M, Togami K, Tabata S, et al: Successful treatment of extranodal natural killer/T-cell lymphoma, nasal type, complicated by severe hemophagocytic syndrome, with dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide chemotherapy followed by autologous stem cell transplant. Leuk Lymphoma. 51:720–723. 2010. View Article : Google Scholar : PubMed/NCBI
43	George MR: Hemophagocytic lymphohistiocytosis: Review of etiologies and management. J Blood Med. 5:69–86. 2014. View Article : Google Scholar : PubMed/NCBI